Disclaimer: This article was published in 2023 and reflects the information available at that time.
In recent weeks, the PDL Professional Officers have received a number of queries regarding pharmacists’ obligations and liability when dispensing Mounjaro® (tirzepatide). Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) re…

Member only access

This content is available to PDL members only.
To continue reading please log in to the member portal or join PDL today.

Share this article
NSW Pharmacy Trial expression of interest closes 15 November
8 November 2023
NSWDispensingProfessional activitiesScope of practiceRegulatory and compliance
Learn more